Clinical Trials · NCT01725126
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 53
- Start date
- Feb 2013
- Locations
- 3 sites, United States
- Primary endpoint
- Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A